Back to top

KalVista (KALV) Advances in Europe with Sebetralstat Approval

KalVista (KALV) Advances in Europe with Sebetralstat Approval

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

KalVista Pharmaceuticals, Inc. (KALV)